Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis
Sponsor: DAS-MG, Inc
Terminated
lack of enrollment
Other Myasthenia Gravis trials with similar outcome
A PHASE2 clinical study on Myasthenia Gravis, this trial is terminated or withdrawn. The trial is conducted by DAS-MG, Inc and has accumulated 10 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
Status: Unknown → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
May 2022 — May 2024 [monthly]
Recruiting PHASE2
-
May 2021 — May 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- DAS-MG, Inc
For direct contact, visit the study record on ClinicalTrials.gov .